Disinfectants In Interventional Practices
Purpose of Review This review aims to provide relevant, aggregate information about a variety of disinfectants and antiseptics, along with potential utility and limitations. While not exhaustive, this review’s goal is to add to the body of literature available on this topic and give interventional providers and practitioners an additional resource to consider when performing procedures. Recent Findings In the current SARS-CoV2 epidemiological environment, infection control and costs associated with healthcare-associated infections (HAIs) are of paramount importance. Even before the onset of SARS-CoV2, HAIs affected nearly 2million patients a year in the USA and resulted in nearly 90,000 deaths, all of which resulted in a cost to hospitals ranging from US$28 billion to 45 billion. The onset SARS-CoV2, though not spread by an airborne route, has heightened infection control protocols in hospitals and, as such, cast a renewed focus on disinfectants and their utility across different settings and organisms. Summary The aim of this review is to provide a comprehensive overview of disinfectants used in the inpatient setting..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current Review of Pain - 25(2021), 4 vom: 11. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aranke, Mayank [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Disinfectants |
|---|
| doi: |
10.1007/s11916-021-00938-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR043454763 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR043454763 | ||
| 003 | DE-627 | ||
| 005 | 20230520011518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210311s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11916-021-00938-3 |2 doi | |
| 035 | |a (DE-627)SPR043454763 | ||
| 035 | |a (DE-599)SPRs11916-021-00938-3-e | ||
| 035 | |a (SPR)s11916-021-00938-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aranke, Mayank |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Disinfectants In Interventional Practices |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose of Review This review aims to provide relevant, aggregate information about a variety of disinfectants and antiseptics, along with potential utility and limitations. While not exhaustive, this review’s goal is to add to the body of literature available on this topic and give interventional providers and practitioners an additional resource to consider when performing procedures. Recent Findings In the current SARS-CoV2 epidemiological environment, infection control and costs associated with healthcare-associated infections (HAIs) are of paramount importance. Even before the onset of SARS-CoV2, HAIs affected nearly 2million patients a year in the USA and resulted in nearly 90,000 deaths, all of which resulted in a cost to hospitals ranging from US$28 billion to 45 billion. The onset SARS-CoV2, though not spread by an airborne route, has heightened infection control protocols in hospitals and, as such, cast a renewed focus on disinfectants and their utility across different settings and organisms. Summary The aim of this review is to provide a comprehensive overview of disinfectants used in the inpatient setting. | ||
| 650 | 4 | |a Disinfectants |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-COV2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inpatient |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Healthcare-associated infections |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Interventional practices |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Moheimani, Roya |e verfasserin |4 aut | |
| 700 | 1 | |a Phuphanich, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D. |e verfasserin |4 aut | |
| 700 | 1 | |a Ngo, Anh L. |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Herman, Jared |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current Review of Pain |d Current Medicine Group, 1998 |g 25(2021), 4 vom: 11. März |w (DE-627)SPR023001666 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2021 |g number:4 |g day:11 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11916-021-00938-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2021 |e 4 |b 11 |c 03 | ||